The use of pramipexole with immediate release in the treatment of restless legs syndrome in patients in psychiatric practice. Questions and answers Review article
Article Sidebar
Published:
Dec 31, 2018
Keywords:
restless legs syndrome, Willis-Ekbom disease, pramipexole
Main Article Content
Abstract
Restless legs syndrome (Willis-Ekbom disease) occurs in 5–15% of the general population. The highest occurrence is in the elderly patients, patients treated with SSRIs and antipsychotics. The best pharmacotherapy for the restless legs syndrome is using pramipexole or rotigotine or cabergoline or gabapentin. Pramipexole can be used once-daily and has the smallest (0.08–0.54 mg) effective dose. This drug is particularly indicated in patients with symptoms of depression and anxiety.
Article Details
How to Cite
Sobów, T. (2018). The use of pramipexole with immediate release in the treatment of restless legs syndrome in patients in psychiatric practice. Questions and answers. Medycyna Faktow (J EBM), 11(4(41), 287-291. https://doi.org/10.24292/01.MF.0418.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Picchietti D.L., Van Den Eeden S.K., Inoue Y., Berger K.: Achievements, challenges and future perpectives of epidemiological research in restless legs syndrome (RLS). Sleep Med. 2017; 31: 3-9.
2. Allen R.P., Picchietti D.L., Garcia-Borreguero D. et al.; International Restless Legs Syndrome Study Group: Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Med. 2014; 15: 860-873.
3. Moeller J.C., Unger M., Stiasny-Kolster K., Oertel W.H.: Restless legs syndrome (RLS) and Parkinson’s disease (PD)-related disorders or different entities. J. Neurol. Sci. 2010; 289: 135-137.
4. Picchietti D., Winkelman J.W.: Restless legs syndrome, periodic limb movements in sleep and depression. Sleep 2005; 28: 891-898.
5. Patatanian E., Claborn M.K.: Drug-induced restless legs syndrome. Ann. Pharmacother. 2018; 52: 662-672.
6. Hoque R., Chesson A.L.: Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J. Clin. Sleep Med. 2010; 6: 79-83.
7. Mitchell U.H.: Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr. Dis. Treat. 2011; 7: 251-257.
8. Harrison E.G., Keating J.L., Morgan P.E.: Non-pharmacological interventions for restless legs syndrome: a systematic review of randomised controlled trials. Disabil. Rehabil. 2018. DOI: 10.1080/09638288.2018.1453875.
9. Winkelman J.W., Armstrong M.J., Allen R.P. et al.: Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016; 87: 2585-2593.
10. Liu G.J., Wu L., Wang S.L. et al.: Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High: Evidence From A Systematic Review and Meta-Analysis. Medicine 2016; 95: e2504.
11. Garcia-Borreguero D., Silber M.H., Winkelman J.W. et al.: Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016; 21: 1-11.
12. Sławek J., Bogucki A., Koziorowski D., Rudzińska M.: Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg – rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Pol. Przegl. Neurol. 2016; 12: 1-14.
13. Zintsaras E., Kitsios G.D., Papathanasiou A.A. et al.: Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. Clin. Ther. 2010; 32: 221-237.
14. Quilici S., Abrams K.R., Nicolas A. et al.: Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. 2008; 9: 715-726.
15. Liu J., Dong J., Wang L. et al.: Comparative efficacy and acceptability of antidepressants in Parkinson’e disease: a network meta-analysis. PLoS One 2013; 8: e76651.
16. Pae C.U.: Pramipexole augmentation in treatment-resistant major depressive disorder. Expert Rev. Neurother. 2014; 14: 5-8.
2. Allen R.P., Picchietti D.L., Garcia-Borreguero D. et al.; International Restless Legs Syndrome Study Group: Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Med. 2014; 15: 860-873.
3. Moeller J.C., Unger M., Stiasny-Kolster K., Oertel W.H.: Restless legs syndrome (RLS) and Parkinson’s disease (PD)-related disorders or different entities. J. Neurol. Sci. 2010; 289: 135-137.
4. Picchietti D., Winkelman J.W.: Restless legs syndrome, periodic limb movements in sleep and depression. Sleep 2005; 28: 891-898.
5. Patatanian E., Claborn M.K.: Drug-induced restless legs syndrome. Ann. Pharmacother. 2018; 52: 662-672.
6. Hoque R., Chesson A.L.: Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J. Clin. Sleep Med. 2010; 6: 79-83.
7. Mitchell U.H.: Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr. Dis. Treat. 2011; 7: 251-257.
8. Harrison E.G., Keating J.L., Morgan P.E.: Non-pharmacological interventions for restless legs syndrome: a systematic review of randomised controlled trials. Disabil. Rehabil. 2018. DOI: 10.1080/09638288.2018.1453875.
9. Winkelman J.W., Armstrong M.J., Allen R.P. et al.: Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016; 87: 2585-2593.
10. Liu G.J., Wu L., Wang S.L. et al.: Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High: Evidence From A Systematic Review and Meta-Analysis. Medicine 2016; 95: e2504.
11. Garcia-Borreguero D., Silber M.H., Winkelman J.W. et al.: Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016; 21: 1-11.
12. Sławek J., Bogucki A., Koziorowski D., Rudzińska M.: Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg – rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Pol. Przegl. Neurol. 2016; 12: 1-14.
13. Zintsaras E., Kitsios G.D., Papathanasiou A.A. et al.: Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. Clin. Ther. 2010; 32: 221-237.
14. Quilici S., Abrams K.R., Nicolas A. et al.: Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. 2008; 9: 715-726.
15. Liu J., Dong J., Wang L. et al.: Comparative efficacy and acceptability of antidepressants in Parkinson’e disease: a network meta-analysis. PLoS One 2013; 8: e76651.
16. Pae C.U.: Pramipexole augmentation in treatment-resistant major depressive disorder. Expert Rev. Neurother. 2014; 14: 5-8.